CN

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology

SUZHOU, CHINA, January 2nd, 2024 -- MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.

2024-01-02Learn more

MediLinks Appoints Jason (Jia) Li as Chief Financial Officer

January 1st, 2024, MediLink Therapeutics solemnly announced the official appointment of Mr. Jason (Jia) Li as the company's chief financial officer (CFO). Mr. Li will report to Dr. Tongtong (Tony) Xue, Chairman and CEO of the company, and will be responsible for the overall financial planning and management, corporate finance and IPO, development strategy and other financial work, so as to promote the internationalization process and further steady development of the company's business, and address more unmet clinical needs.

2024-01-01Learn more

MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences

SUZHOU, CHINA, December 15th , 2023 -- MediLink Therapeutics (“MediLink”), today announced that it has entered into a supplemental agreement to the license agreement with Nona Biosciences (“Nona”, a wholly-owned subsidiary of HBM Holdings) in which Nona is entitled to license the ADC product HBM9033 (YL215) jointly developed by the two parties to a licensed independent third party., Pfizer Inc.. (“Pfizer”). MediLink has the right to receive a certain percentage of sub-licensing payment based on the collaboration between Nona and Pfizer.

2023-12-15Learn more

MediLink Therapeutics Welcomes Steve Chin, M.D., As Chief Medical Officer (CMO)

On Oct. 23rd, 2023, MediLink Therapeutics is pleased to announce the appointment of Dr. Steve Chin as Chief Medical Officer (CMO). Dr. Chin will be responsible for MediLink’s clinical trial execution, product registration and optimization of clinical capability in both China and the US.

2023-10-23Learn more

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate (“ADC”), against Human Epidermal Growth Factor Receptor 3 (HER3).

2023-10-12Learn more

MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment

GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The chair of this meeting was Professor Li Zhang, from the Cancer Center of Sun Yat-sen University, who gathered the wisdom and experience of experts, to discuss the development strategy of the clinical trial protocol in depth, and lay a solid foundation for the efficient drug development of YL201.

2023-09-23Learn more

MediLink Therapeutics is studying YL202 in advanced lung and breast cancer patients.

Working as a Clinical Research Coordinator I frequently find myself in the situation of balancing trial demands, patients’ comfort and executing protocol instructions correctly. I make the best of my resources and ask for assistance when needed. Hence, it should go without saying, having a reliable team is of paramount importance! Here is where, in my most recent experience, MediLink Therapeutics excels.

2023-08-25Learn more

PHARMCUBE interview - Dr. Xue, founder of Medilink Therapeutics

2023-03-02Learn more

1 2 3